Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [09/04/2025 10:29 PDT] Savara Inc. (NASDAQ:SVRA), Up By 100% ($3.06) After BUYINS.NET SqueezeTrigger Report Released on Thursday, August 14th 2025 at a Price of $3.055.
• [08/14/2025 12:43 PDT] Savara Inc. (NASDAQ:SVRA), Up By 100% ($2.58) From $2.58 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/14/2025 12:42 PDT] SVRA SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [08/13/2025 07:08 PDT] SVRA Expected to Trade Up After Bullish Patterns Develop